Patients who received newer P2Y12 inhibitors displayed important differences compared with those treated with clopidogrel, which included: a younger age, a higher frequency of males, STEMI at presentation, and a lower frequency of renal failure. The gene discussed is P2RY12; the disease is kidney failure.